SPL Starpharma receives $4.0M R&D tax incentive refund 12/03/19 PRICE SENSITIVE Share SPL Interim Report and Half-Yearly Financial Results 27/02/19 PRICE SENSITIVE Share SPL Quarterly Cashflow Report 30/01/19 PRICE SENSITIVE Share SPL Response to ASX Aware Letter 07/01/19 PRICE SENSITIVE Share SPL VivaGel condom receives final regulatory approval in Japan 02/01/19 PRICE SENSITIVE Share SPL US FDA requests further data for VivaGel BV approval 27/12/18 PRICE SENSITIVE Share SPL US VivaGel BV licensed for A$142M milestones plus royalties 20/12/18 PRICE SENSITIVE Share SPL AGM - Chairman address and CEO presentation 29/11/18 PRICE SENSITIVE Share SPL DEP products outperform in human pancreatic cancer model 16/11/18 PRICE SENSITIVE Share SPL Quarterly Cashflow Report 26/10/18 PRICE SENSITIVE Share SPL Starpharma Investor Presentation for Citi Conference 17/10/18 PRICE SENSITIVE Share SPL DEP irinotecan outperforms in pancreatic cancer model 05/09/18 PRICE SENSITIVE Share SPL AstraZeneca DEP Bcl2/xL inhibitors show compelling efficacy 31/08/18 PRICE SENSITIVE Share SPL Annual report and full year financial results 21/08/18 PRICE SENSITIVE Share SPL Quarterly Cashflow Report 17/07/18 PRICE SENSITIVE download Created with Sketch. 227.14KB Share SPL VivaGel BV NDA advances to next stage of FDA review 09/07/18 PRICE SENSITIVE download Created with Sketch. 119.38KB Share SPL Starpharma licenses VivaGel BV to Mundipharma for Europe 27/06/18 PRICE SENSITIVE download Created with Sketch. 141.64KB Share SPL Mundipharma licenses Starpharma's VivaGel BV 03/05/18 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Report 30/04/18 PRICE SENSITIVE Share SPL Starpharma completes US New Drug Application for VivaGel BV 30/04/18 PRICE SENSITIVE Share SPL Interim Report and Half-Yearly Financial Results 26/02/18 PRICE SENSITIVE Share SPL Starpharma receives $3.7M R&D tax incentive refund 22/02/18 PRICE SENSITIVE Share SPL Starpharma to commence DEP cabazitaxel phase 1/2 trial 31/01/18 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Report 25/01/18 PRICE SENSITIVE Share SPL VivaGel BV treatment clinical submission under rolling NDA 21/12/17 PRICE SENSITIVE Share SPL NDA submission for VivaGel BV in the US 21/11/17 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Report 26/10/17 PRICE SENSITIVE Share SPL VivaGel BV granted marketing approval in Australia 25/10/17 PRICE SENSITIVE Share SPL Starpharma and Peter Mac Cancer Centre awarded DEP Grant 09/10/17 PRICE SENSITIVE Share SPL AstraZeneca presents 1st DEP candidate as Bcl2/xL inhibitor 28/09/17 PRICE SENSITIVE Share SPL DEP docetaxel positive phase 1 results, phase 2 commences 22/09/17 PRICE SENSITIVE Share SPL Annual report and full year financial results 28/08/17 PRICE SENSITIVE Share SPL Starpharma and Monash awarded STEM Business Fellowships 09/08/17 PRICE SENSITIVE Share SPL Successful VivaGel Phase 3 results and NDA planned for rBV 07/08/17 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Report 19/07/17 PRICE SENSITIVE Share SPL VivaGel BV phase 3 results timing and commercialisation 04/07/17 PRICE SENSITIVE Share SPL Starpharma sells Agrochemicals business to Agrium for $35M 14/06/17 PRICE SENSITIVE Share SPL DEP irinotecan outperforms irinotecan in cancer models 06/06/17 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Report 28/04/17 PRICE SENSITIVE Share SPL AstraZeneca DEP candidate advance triggers milestone to SPL 20/04/17 PRICE SENSITIVE Share SPL Ansell launches VivaGel condom in Canada 12/04/17 PRICE SENSITIVE Share SPL VivaGel BV phase 3 trials for prevention of BV completed 30/03/17 PRICE SENSITIVE Share SPL Interim Report and Half-Year Financial Results 27/02/17 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Report 31/01/17 PRICE SENSITIVE Share SPL Shareholder Update January 2017 19/01/17 PRICE SENSITIVE Share SPL VivaGel BV granted QIDP and Fast Track designation by US FDA 12/01/17 PRICE SENSITIVE Share SPL Starpharma receives $3.5M R&D tax incentive refund 22/12/16 PRICE SENSITIVE Share SPL Starpharma signs license for VivaGel Condom in Iran 28/11/16 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Report-SPL.AX 28/10/16 PRICE SENSITIVE Share SPL Additional Priostar Glyphosate Patent Allowed in US-SPL.AX 28/10/16 PRICE SENSITIVE Share SPL Enrolment complete for Phase 3 VivaGel BV-R program-SPL.AX 13/10/16 PRICE SENSITIVE Share SPL VivaGel condom receives regulatory approval in Canada-SPL.AX 13/09/16 PRICE SENSITIVE Share SPL Annual report and full year financial results-SPL.AX 29/08/16 PRICE SENSITIVE Share SPL New DEP drug delivery program initiated with AstraZeneca-SPL.AX 28/07/16 PRICE SENSITIVE Share SPL Starpharma signs license for a VivaGel condom in China-SPL.AX 21/07/16 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Reoprt-SPL.AX 14/07/16 PRICE SENSITIVE Share SPL Starpharma's DEP eliminates cabazitaxel neutropenia-SPL.AX 25/05/16 PRICE SENSITIVE Share SPL VivaGel active against Zika virus-SPL.AX 05/05/16 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Report-SPL.AX 28/04/16 PRICE SENSITIVE Share SPL DEP cabazitaxel shows complete, sustained tumour regression-SPL.AX 04/04/16 PRICE SENSITIVE Share SPL Adama Licenses Starpharma's Priostar for Novel 2,4-D 17/03/16 PRICE SENSITIVE Share SPL Starpharma licences VivaGel BV to Aspen for ANZ 04/03/16 PRICE SENSITIVE Share SPL Interim Report and Half-Year Financial Results 17/02/16 PRICE SENSITIVE Share SPL Targeted DEP shows sustained superior performance 02/02/16 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Report 28/01/16 PRICE SENSITIVE Share SPL Starpharma raises $1.9M under Share Purchase Plan 20/01/16 PRICE SENSITIVE Share SPL Starpharma signs MOU for VivaGel condom in China 16/12/15 PRICE SENSITIVE Share SPL Starpharma completes A$32 million placement 09/12/15 PRICE SENSITIVE Share SPL Trading Halt 07/12/15 PRICE SENSITIVE Share SPL DEP outperforms leading treatments in ovarian cancer model 16/11/15 PRICE SENSITIVE Share SPL Starpharma receives $3.4M R&D tax incentive 12/11/15 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Report 30/10/15 PRICE SENSITIVE Share SPL Additional US Patent Granted for VivaGel BV 14/10/15 PRICE SENSITIVE Share SPL EU Marketing Approval Granted for VivaGel BV 24/09/15 PRICE SENSITIVE Share SPL Starpharma signs drug delivery license with AstraZeneca 07/09/15 PRICE SENSITIVE Share SPL Annual report and full year financial results 21/08/15 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Report 30/07/15 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Report 30/04/15 PRICE SENSITIVE Share SPL DEP Docetaxel Trial Dose Exceeds Common Taxotere Dose Level 30/04/15 PRICE SENSITIVE Share SPL Interim Report and Half-Year Financial Results 16/02/15 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Report 28/01/15 PRICE SENSITIVE Share SPL Japan VivaGel condom classification impacts launch timing 05/12/14 PRICE SENSITIVE Share SPL Marketing Clearance for VivaGel condom in New Zealand 28/11/14 PRICE SENSITIVE Share SPL Response to ASX Price Query 17/11/14 PRICE SENSITIVE Share SPL Starpharmas Priostar Glyphosate Patent Allowed in China 13/11/14 PRICE SENSITIVE Share SPL Appendix 4C - quarterly 31/10/14 PRICE SENSITIVE Share SPL Starpharma receives $4.2M R&D tax incentive refund 29/10/14 PRICE SENSITIVE Share SPL DEP docetaxel - longer duration and increased exposure 20/10/14 PRICE SENSITIVE Share SPL VivaGel condom approved for sale with launch imminent 02/10/14 PRICE SENSITIVE Share SPL SPP Record Date Clarification 22/09/14 PRICE SENSITIVE Share SPL Starpharma completes A$18 million placement, SPP to follow 22/09/14 PRICE SENSITIVE Share SPL Trading Halt 18/09/14 PRICE SENSITIVE Share SPL Annual report and full year financial results 13/08/14 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Report 31/07/14 PRICE SENSITIVE Share SPL VivaGel condom receives TGA device certification 21/07/14 PRICE SENSITIVE Share SPL FDA Grants SPA Agreement for Phase 3 Recurrent BV Trial 14/07/14 PRICE SENSITIVE Share SPL Starpharma clinical trial programs accelerating 05/06/14 PRICE SENSITIVE Share SPL Appendix 4C - Quarterly Cashflow Report 30/04/14 PRICE SENSITIVE Share SPL Starpharma expands Drug Delivery Program with AstraZeneca 07/04/14 PRICE SENSITIVE Share SPL VivaGel-coated condom approved for marketing in Japan 14/03/14 PRICE SENSITIVE Share
10.5¢
(20min delay)
